Oxidative modifications of cerebral transthyretin are associated with multiple sclerosis

Pieragostino, Damiana; Boccio, Piero Del; Ioia, Maria di; Pieroni, Luisa; Greco, Viviana; Luca, Giovanna De; D’Aguanno, Simona; Rossi, Cláudia; Franciotta, Diego; Centonze, Diego; Sacchetta, Paolo; Ilio, Carmine Di; Lugaresi, Alessandra; Urbani, Andrea

doi:10.1002/pmic.201200395

Cited by 23 publications

(20 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, as previously described, degradation of CysC could be strongly linked to sample storage [16]. Figure 4 shows how a state of oxidation could be linked to a state of disease [37]. The high resolution of the In vitro CSF TTR modification revealed in MALDI-TOF spectrum.…”

Section: Dasqmentioning

confidence: 62%

See 1 more Smart Citation

Direct analytical sample quality assessment for biomarker investigation: Qualifying cerebrospinal fluid samples

et al. 2014

Self Cite

View full text Add to dashboard Cite

Measurement of biochemical markers represents an important aid to clinicians in the early diagnosis and prognosis of neurological diseases. Many factors can contribute to increase the chances that a biomarker study becomes successful. In a cerebrospinal fluid analysis (CSF), more than 84% of laboratory errors can be attributed to several preanalytical variables that include CSF collection, storage, and freeze thawing cycles. In this concept paper, we focus on some critical issues arising from basic proteomics investigation in order to highlight some key elements of CSF quality control. Furthermore, we propose a direct assessment of sample quality (DASQ) by applying a fast MALDI-TOF-MS methodology to evaluate molecular features of sample degradation and oxidation. We propose DASQ as a fast and simple initial step to be included in large-scale projects for neurological biomarker studies. In fact, such a procedure will improved the development of standardized protocols in order to have well-characterized CSF biobanks.

show abstract

Section: Dasqmentioning

confidence: 62%

“…Figure shows how a state of oxidation could be linked to a state of disease . The high resolution of the linear MALDI‐TOF‐MS method in this specific range allows to identify high levels of sulfydration (–SH) and sulfonation (–SO3H) of TTR ex vivo in MS affected patients compared to OND patients.…”

Section: Dasqmentioning

confidence: 99%

Direct analytical sample quality assessment for biomarker investigation: Qualifying cerebrospinal fluid samples

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…The explication of this result may be found in the possible posttranslational modifications (PTMs) that occur in TTR. Actually as demonstrated by our group, TTR may undergo to oxidative PTMs that may dramatically change its folding and function [109]. Anyway the role of this protein in MuS CSF and serum should be further elucidated and validated in a more exhaustive casuistry.…”

Section: Proteomic Mus Biomarkersmentioning

confidence: 81%

Integration of metabolomics and proteomics in multiple sclerosis: From biomarkers discovery to personalized medicine

Boccio

Rossi

Ioia

et al. 2016

Proteomics Clinical Apps

Self Cite

View full text Add to dashboard Cite

Personalized medicine is the science of individualized prevention and therapy. In the last decade, advances in high-throughput approaches allowed the development of proteomic and metabolomic studies in evaluating the association of genetic and phenotypic variability with disease sensitivity and analgesic response. These considerations have more value in case of multiple sclerosis (MuS), a multifactorial disease with high heterogeneity in clinical course and treatment response. In this review, we reported and updated about proteomic and metabolomic studies for the research of new candidate biomarkers in MuS, and difficulties in their clinical applications. We focused especially on the description of both "omics" approaches that, once integrated, may synergically describe pathophysiology conditions. To prove this assumption, we rebuilt interaction between proteins and metabolites described in the literature as potential biomarkers for MuS, and a pathway analysis of these molecules was performed. The result of such speculation demonstrated a strong convergence of proteomic and metabolomic results in this field, showing also a poorness of available tools for incorporating "omics" approaches. In conclusion, the integration of Metabolomics and Proteomics may allow a more complete characterization of such a heterogeneous disease, providing further insights into personalized healthcare.

show abstract

“…Differentially expressed SNO-proteins were mainly involved in metabolism, cell cytoskeleton/structure, immune system, cell-cell communication, and miscellaneous function protein. Proteomic studies of cysteine PTMs in other neurodegenerative diseases, such as Huntington disease, amyotrophic lateral sclerosis and Down syndrome, are very limited [164].…”

Section: Other Neurodegenerative Diseasesmentioning

confidence: 99%

Proteomic approaches to quantify cysteine reversible modifications in aging and neurodegenerative diseases

Robinson

2016

Proteomics Clinical Apps

View full text Add to dashboard Cite

Cysteine is a highly reactive amino acid and is subject to a variety of reversible post-translational modifications (PTMs), including nitrosylation, glutathionylation, palmitoylation, as well as formation of sulfenic acid and disulfides. These modifications are not only involved in normal biological activities, such as enzymatic catalysis, redox signaling and cellular homeostasis, but can also be the result of oxidative damage. Especially in aging and neurodegenerative diseases, oxidative stress leads to aberrant cysteine oxidations that affect protein structure and function leading to neurodegeneration as well as other detrimental effects. Methods that can identify cysteine modifications by type, including the site of modification, as well as the relative stoichiometry of the modification can be very helpful for understanding the role of the thiol proteome and redox homeostasis in the context of disease. Cysteine reversible modifications however, are challenging to investigate as they are low abundant, diverse, and labile especially under endogenous conditions. Thanks to the development of redox proteomic approaches, large-scale quantification of cysteine reversible modifications is possible. These approaches cover a range of strategies to enrich, identify, and quantify cysteine reversible modifications from biological samples. This review will focus on nongel-based redox proteomics workflows that give quantitative information about cysteine PTMs and highlight how these strategies have been useful for investigating the redox thiol proteome in aging and neurodegenerative diseases.

show abstract

Oxidative modifications of cerebral transthyretin are associated with multiple sclerosis

Cited by 23 publications

References 36 publications

Direct analytical sample quality assessment for biomarker investigation: Qualifying cerebrospinal fluid samples

Direct analytical sample quality assessment for biomarker investigation: Qualifying cerebrospinal fluid samples

Integration of metabolomics and proteomics in multiple sclerosis: From biomarkers discovery to personalized medicine

Proteomic approaches to quantify cysteine reversible modifications in aging and neurodegenerative diseases

Contact Info

Product

Resources

About